Concepedia

Publication | Open Access

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

DOIFull Paper Access

188

Citations

11

References

2022

Year

Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Frank Behrens, Alan Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee
Annals of the Rheumatic Diseases

References

YearCitations

Page 1